Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

The primary endpoint was the number of patients requiring red blood cells transfusion after randomization and during hospital stay.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

More than one site took part, so the participants came from several places.

Secondary end points were: blood loss from chest tubes during the first 24 h after study drug administration, hours of mechanical ventilation, intensive care unit stay, and in-hospital mortality.

What Was Measured

Topics PubMed links to this paper include Cardiac Surgical Procedures, Deamino Arginine Vasopressin, Hemostatics and Postoperative Hemorrhage.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Acta anaesthesiologica Scandinavica), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.